TD Cowen analyst Charles Rhyee raised the firm’s price target on CVS Health (CVS) to $80 from $73 and keeps a Buy rating on the shares. The firm said it remains a Best Idea for 2025 and while a high risk pick, they see potential upside of +40% worth it. We view 2024 as a bottom for shares as CVS has set itself up for a significant MA turnaround in 2025 after a successful 2025 bid process and redesign of MA benefits.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVS:
- CVS Health price target lowered to $64 from $72 at Piper Sandler
- Trump Weekly: Trump looks to drop EV tax credit, fuel-efficiency requirements
- Trump Trade: Transition team weighing White House crypto role
- CVS (NYSE:CVS), UnitedHealth and Cigna File Suit Against the Federal Trade Commission
- Kennedy Jr. considers upheaval to U.S. Medicare billing system, FT says
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
